| 51 |
21095630 | Epidermal growth factor receptor expression modulates antitumor efficacy of vandetanib or cediranib combined with radiotherapy in human glioblastoma xenografts. | 2012 Jan 1 |
3 |
| 52 |
22025146 | Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. | 2012 Jan 10 |
1 |
| 53 |
22075979 | Vascular endothelial growth factor receptor 2 inhibition in-vivo affects tumor vasculature in a tumor type-dependent way and downregulates vascular endothelial growth factor receptor 2 protein without a prominent role for miR-296. | 2012 Feb |
1 |
| 54 |
22158569 | Vandetanib for the treatment of thyroid cancer. | 2012 Jan |
2 |
| 55 |
22184381 | Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. | 2012 Feb 10 |
1 |
| 56 |
22206795 | Pharmacokinetics of vandetanib: three phase I studies in healthy subjects. | 2012 Jan |
1 |
| 57 |
22245891 | Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study. | 2012 May |
1 |
| 58 |
22258476 | Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer. | 2012 Mar |
5 |
| 59 |
22307735 | Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinoma. | 2012 Sep |
3 |
| 60 |
22336242 | [Vandetanib treatment in refractory advanced lung adenocarcinoma patients: five cases and review of literature]. | 2012 Feb |
1 |
| 61 |
22343387 | Recent advances in the molecular pathogenesis and targeted therapies of medullary thyroid carcinoma. | 2012 May |
2 |
| 62 |
22370318 | Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). | 2012 Apr 1 |
4 |
| 63 |
22378813 | Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis. | 2012 Apr |
1 |
| 64 |
22429581 | [Vandetanib for advanced non-small cell lung cancer: a meta-analysis]. | 2012 Mar |
2 |
| 65 |
22484209 | Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin. | 2012 Aug 15 |
1 |
| 66 |
22500115 | Role of vandetanib in the management of medullary thyroid cancer. | 2012 |
1 |
| 67 |
22505191 | Combined therapy of temozolomide and ZD6474 (vandetanib) effectively reduces glioblastoma tumor volume through anti-angiogenic and anti-proliferative mechanisms. | 2012 Jul |
2 |
| 68 |
22548830 | Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance. | 2012 Aug 1 |
1 |
| 69 |
22646768 | Inhibition of non-small-cell lung cancer growth by combined fulvestrant and vandetanib. | 2012 May |
1 |
| 70 |
22667325 | Vandetanib for the treatment of lung cancer. | 2012 Aug |
1 |
| 71 |
22701615 | Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer. | 2012 |
1 |
| 72 |
22715896 | Vandetanib: in medullary thyroid cancer. | 2012 Jul 9 |
2 |
| 73 |
22898678 | Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. | 2012 Sep |
1 |
| 74 |
23099652 | A phase I/II trial of vandetanib for patients with recurrent malignant glioma. | 2012 Dec |
1 |
| 75 |
20665703 | ZD6474 enhances paclitaxel antiproliferative and apoptotic effects in breast carcinoma cells. | 2011 Feb |
2 |
| 76 |
20943719 | The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. | 2011 Feb |
6 |
| 77 |
21247406 | Emerging therapies in the treatment of locally advanced squamous cell cancers of head and neck. | 2011 May |
1 |
| 78 |
21282537 | Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. | 2011 Mar 10 |
1 |
| 79 |
21282542 | Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. | 2011 Mar 10 |
1 |
| 80 |
21350000 | Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro. | 2011 Apr 1 |
2 |
| 81 |
21537841 | Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer. | 2011 Jul |
7 |
| 82 |
21600385 | Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study. | 2011 Mar |
2 |
| 83 |
21723791 | Integration of EGFR inhibitors and conventional chemotherapy in the treatment of non-small-cell lung cancer. | 2011 Nov |
1 |
| 84 |
21770481 | Vandetanib: first global approval. | 2011 Jul 9 |
4 |
| 85 |
21819274 | Vandetanib for the treatment of non-small-cell lung cancer. | 2011 Oct |
1 |
| 86 |
21836817 | Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer. | 2011 |
4 |
| 87 |
21921646 | Phase I dose-finding study of vandetanib in combination with gemcitabine in locally advanced unresectable or metastatic pancreatic adenocarcinoma. | 2011 |
1 |
| 88 |
21970874 | Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin. | 2011 Nov 8 |
3 |
| 89 |
22346266 | Photosensitivity reactions to vandetanib: redevelopment after sequential treatment with docetaxel. | 2011 Dec |
2 |
| 90 |
22393954 | Efficacy and safety of vandetanib, a dual VEGFR and EGFR inhibitor, in advanced non-small-cell lung cancer: a systematic review and meta-analysis. | 2011 |
2 |
| 91 |
23148184 | Thyroid cancer: pathogenesis and targeted therapy. | 2011 Oct |
1 |
| 92 |
20065189 | Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. | 2010 Feb 10 |
1 |
| 93 |
20068097 | Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2. | 2010 Jan 15 |
1 |
| 94 |
20137866 | Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. | 2010 Sep 1 |
1 |
| 95 |
20139705 | ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells. | 2010 Apr 15 |
3 |
| 96 |
20225331 | A novel therapeutic combination for neuroblastoma: the vascular endothelial growth factor receptor/epidermal growth factor receptor/rearranged during transfection inhibitor vandetanib with 13-cis-retinoic acid. | 2010 May 15 |
2 |
| 97 |
20371720 | ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain. | 2010 Apr |
5 |
| 98 |
20570559 | Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. | 2010 Jul |
2 |
| 99 |
20661087 | A phase I study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer. | 2010 Aug |
1 |
| 100 |
20859451 | Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer. | 2010 Sep 13 |
4 |